Archives for February 16, 2006

← 2006

Singapore MTI announces S$7.5bn investment

By Wai Lang Chu

Singapore's commitment to pharmaceutical research and development goes from strength to strength after its government granted S$7.5bn (€3.9bn) to sustain the innovation-driven growth the country has experienced as Asia's main drug research hub.

New ReactArray Solo aids drug patent protection

By  Wai Lang Chu

A collaboration between Anachem and chemists within the pharmaceutical industry has resulted in the launch of the new ReactArray Solo, which is designed to provide faster, more efficient polymorph screening to aid drug patent protection by enabling...

Scientists stumble on potential arthritis drug target

By  Wai Lang Chu

Scientists exploring inflammation in rheumatoid arthritis have made an unexpected discovery that may lead to new drug treatments to ease the pain and discomfort endured by 66 million (nearly 1 in 3 adults) US citizens in 2005.

Q3 revenues dip for Pharsight

By Kirsty Barnes

Pharsight, a provider of software and strategic services for clinical drug development, has seen its revenues dip for the second quarter in a row due to lower-than-expected business from a top client in its strategic consulting services segment.

Two new contracts for Celsis

By Kirsty Barnes

Celsis Laboratory Group has won two new contracts with URL Mutual Pharmaceutical and Procter & Gamble for the provision of contract testing services.

Honeywell launches improved BMI activator

By  Wai Lang Chu

Honeywell launches a new formulation of BMI activator, which is used to synthesise DNA and RNA oligonucleotides for therapeutic and medical diagnostic applications. The formulation aims to result in higher yields and lower overall operational costs...

SIPLAS sign agreement for clinical trial support

By  Wai Lang Chu

Contract Research Organisation (CRO) Averion, and the SIPLAS Research Organisation has signed an agreement to provide promotion and support of clinical trials in a move that that reinforces Latin America as an emerging hub of clinical trial service...

Ventiv to buy Adheris

By Kirsty Barnes

Ventiv, which conducts clinical, sales, marketing and communications services for the pharma industry, has added a new arm to its business after agreeing to buy Adheris, a leading provider of patient adherence programs.